Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR: BULLS AND BEARS! -- Ignore unavailable to you. Want to Upgrade?

To: OLD JAKE JUSTUS who wrote (5753)	4/30/1998 1:46:00 PM
From: DAN LITTLE	Read Replies (2) \| Respond to of 8902

Jake, can you imagine what the sales would look like if their drug also faught against HPV, Hepatitis, Herpes, Influenza, Arthritis and I'm sure a few I've forgotten. It boggles the mind. $50.00? Maybe I'd better reevaluate. Dan "AIDS: The New Drug War" Fortune (04/27/98) Vol. 137, No. 8, P. 60; Smith, Liz Glaxo-Wellcome's AZT, which has been the principal drug over the past 10 years in the fight against AIDS, is getting some stiff competition from Bristol-Myers Squibb's Zerit. Patients seem to tolerate Zerit better than AZT and do not build resistance to the drug as fast. Monthly prescriptions for Zerit surged past AZT last December. To stem the threat to its market share, Glaxo Wellcome last October introduced Combivir, a pill that combines AZT and 3TC. But annual sales of AZT and Combivir combined rose only 7 percent in 1997 to $472 million, while year-on-year market share to February dropped from 29.3 percent to 16.5 percent. Meanwhile, Zerit's 1997 sales surged 185 percent to $389 million, and sales are expected to exceed $600 million for this year.